Strota/ Newsroom/ 2026-09-30

GLENMARK slid -4.4% on at day's low

Strota Newsroom · session of 2026-09-30 · market close · GLENMARK stock page →

Glenmark Pharmaceuticals Ltd. (GLENMARK) slid -4.4% to ₹2,334.70 with 5 signals firing. Here is what the exchange data shows.

Glenmark Pharmaceuticals ended the session at ₹2,334.70, down 4.37% from the previous close of ₹2,441.50, and that closing print was also the low of the day. The wider market was far calmer, with the Nifty slipping 0.42%, so most of the damage was specific to Glenmark rather than a market-wide drag. The stock opened on a gap-down of 2.07%, managed an intraday high of ₹2,410, which never got back to the prior close, and then gave ground through the day to finish at the bottom of its range.

There is no open-interest classification for the day: the pack's F&O positioning field is empty, so it cannot say whether the fall came with fresh short positions or with longs being closed. What the live signals did capture is a futures discount of 1.92%, meaning futures were quoted below the cash price, and the stock trading 1.78% below VWAP (the volume-weighted average price paid across the session). Both describe a day on which sellers kept the upper hand into the close.

Participation was heavy, although the pack gives two different readings of how heavy. The live signal flags a volume spike of 4.2x normal, while the technicals block puts relative volume at 2.58x. The two may be measured against different baselines or at different times, and the pack does not reconcile them; either way, turnover was well above an ordinary day.

The institutional footprint is blank. There is no record of bulk or block deals in the last 30 days, no insider filings in the last 60 days, and no deals flagged for today, so the data offers no sign of a large named buyer or seller behind the move.

On the technical picture, which may be stamped to an earlier close rather than today's final price, the 14-day RSI (a momentum gauge running from 0 to 100) read 43.5. The stock sat below its 50-day moving average but above its 200-day average, about 8% under its 52-week high and 30.24% above its 52-week low. It had lost roughly 5.66% over a week and 5.49% over a month.

The only fresh company news is a report on scanx.trade that Glenmark has launched GLIPIQ, a semaglutide product, in India with weekly treatment starting at ₹325. The feed timestamps that item late in the day, after the gap-down open, and the pack says nothing about how the market read it. Older context is mixed: a week earlier Business Today reported that the company's Goa facility received VAI status after a USFDA inspection, and a Business Standard headline eight days ago described a fifth straight session of gains.

Taken together, the data shows no single obvious catalyst. The visible footprints are a gap-down open, volume well above normal, futures at a discount, and a close at the day's low while the index fell far less. The semaglutide launch report is the one new headline, but nothing in the evidence links it to the selling, and its timing sits after the opening drop.

The numbers

Signals that fired

Technical context

Volume ran at 2.6× its 20-day average; rsi(14) sits at 44; price is 8.0% from the 52-week high; trading above the 200-dma.

Recent headlines

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.